All In Biotech

Drug Trial Radar · NCT06984926

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3810477 in Healthy Male and Female Trial Participants (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jun 6, 2025

Primary completion

Mar 9, 2026

Study completion Mar 9, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.

Conditions

  • Healthy

Interventions

  • BI 3810477Drug

    BI 3810477

  • PlaceboDrug

    Placebo for BI 3810477

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of any treatment-emergent adverse events assessed as drug-related by the investigatorTime frame: Up to Day 117

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Life Science Services - Clinical Research

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.